Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 7/20 | 0.77 |
| ▸ | FOLH1 | Q04609 | 13/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19743080 | 1.00 | ALB (0.77) | ALBFOLH1 | |
| SCHEMBL19743100 | 0.97 | ALB (0.72) | ALBFOLH1 | |
| SCHEMBL19743101 | 0.97 | ALB (0.72) | ALBFOLH1 | |
| SCHEMBL19743078 | 0.94 | FOLH1 (0.71) | ALBFOLH1 | |
| SCHEMBL19743077 | 0.94 | FOLH1 (0.71) | ALBFOLH1 | |
| SCHEMBL19747822 | 0.93 | FOLH1 (0.70) | ALBFOLH1 | |
| SCHEMBL19743111 | 0.89 | FOLH1 (0.72) | ALBFOLH1 | |
| SCHEMBL19743110 | 0.89 | FOLH1 (0.72) | ALBFOLH1 | |
| SCHEMBL18770762 | 0.88 | FOLH1 (0.63) | ALBFOLH1 | |
| SCHEMBL19748972 | 0.87 | FOLH1 (0.68) | ALBFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091008-A1 | DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL | CORNELL UNIVERSITY (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4520745-A2 | DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL | Cornell University (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-3474903-B1 | DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL | UNIV CORNELL (US) | 2025-01-22 | — | — | EP | disclosed |
| US-12186288-B2 | Double targeted constructs to affect tumor kill | CORNELL UNIVERSITY (US) | 2025-01-07 | — | — | US | disclosed |
| US-20210137860-A1 | DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL | CORNELL UNIVERSITY (US) | 2021-05-13 | — | — | US | disclosed |
| US-10716772-B2 | Double targeted constructs to affect tumor kill | CORNELL UNIVERSITY (US) | 2020-07-21 | — | — | US | disclosed |
| US-20190142770-A1 | DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL | CORNELL UNIVERSITY | 2019-05-16 | — | — | US | disclosed |
| US-10179117-B2 | Double targeted constructs to affect tumor kill | CORNELL UNIVERSITY (US) | 2019-01-15 | — | — | US | disclosed |
| US-20170368005-A1 | DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL | CORNELL UNIVERSITY | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091008-A1 | DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL | PSMA2, CD47, KLK3 | ALB 1858/4885FOLH1 5/4885 |
| US-20210137860-A1 | DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL | PSMA2, FOLH1, KLK3 | ALB 1812/4885FOLH1 2/4885 |
| US-12186288-B2 | Double targeted constructs to affect tumor kill | PSMA2, FOLH1, KLK3 | ALB 1812/4885FOLH1 2/4885 |
| US-10716772-B2 | Double targeted constructs to affect tumor kill | PSMA2, FOLH1, KLK3 | ALB 1812/4885FOLH1 2/4885 |
| US-20170368005-A1 | DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL | PSMA2, FOLH1, KLK3 | ALB 1812/4885FOLH1 2/4885 |
| US-20190142770-A1 | DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL | PSMA2, FOLH1, KLK3 | ALB 1812/4885FOLH1 2/4885 |
| US-10179117-B2 | Double targeted constructs to affect tumor kill | PSMA2, FOLH1, KLK3 | ALB 1812/4885FOLH1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.